Business · 09/04/2014Updated: 10/17/2026 · 1 min read
FDA Extends Comment Period for Draft Guidance on Blood Glucose Monitoring Test Systems
Summary
The FDA is extending the comment period for its draft guidance on blood glucose monitoring test systems for prescription point-of-care use until May 7, 2014, in response to requests for an extension from interested persons.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →